已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies.

医学 成纤维细胞生长因子受体 肿瘤科 内科学 成纤维细胞生长因子 受体
作者
Shubham Pant,Joon Oh Park,Wu‐Chou Su,Martin Schüler,Yohann Loriot,Gopa Iyer,Toshihiko Doi,Shukui Qin,Josep Tabernero,Hans Prenen,Gunnar Folprecht,Helen Winter,Graziela Zibetti Dal Molin,Hussein Sweiti,Saltanat Najmi,Constance Hammond,Huimin Liao,Shibu Thomas,Spyros Triantos,Yin‐Hsun Feng
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): 4121-4121
标识
DOI:10.1200/jco.2024.42.16_suppl.4121
摘要

4121 Background: Erdafitinib is an oral selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor approved in the US for the treatment of adult pts with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alterations whose disease has progressed on or after ≥1 line of prior systemic therapy. Primary analysis of the RAGNAR study demonstrated tumor agnostic efficacy in patients with solid tumors harboring susceptible FGFR mutations or fusions (1). Results from the LUC2001 study in patients with cholangiocarcinoma were previously presented (2). Here we report on the pooled analysis of patients with cholangiocarcinoma treated in the RAGNAR and LUC2001 studies. Methods: RAGNAR (NCT04083976) and LUC2001 (NCT02699606) enrolled patients with advanced solid tumors after ≥1 prior lines of therapy. RAGNAR patients had exhausted standard of care therapies; LUC2001 enrolled patients only in China, Taiwan, and South Korea. Patients received erdafitinib (8 mg daily, optional up-titration) until disease progression or toxicity. Patients with cholangiocarcinoma and predefined FGFR alterations were pooled into an analysis of efficacy (objective response rate by Independent Review Committee [IRC], duration of response, progression free survival, overall survival) and safety. Results: At data cutoff, 78 patients had received erdafitinib (RAGNAR: 66; LUC2001: 12). Median efficacy follow-up was 15 months. Median (range) age was 56 years (24;77); 60% female, 47% White, 39% Asian. Patients had a median of 2 prior lines of therapy; 92% patients had visceral metastases, and 17% of patients responded to prior therapy. 94% of patients had FGFR2 alterations, and 91% of patients had fusions. Objective response rate by IRC was 55%. Responses were observed in patients with both, fusions or mutations. Median time to onset of response was 1.7 month; median duration of response, progression free survival, and overall survival were 6.9 (95% CI: 4.37, 8.61), 8.5 (95% CI: 6.83, 9.72), and 18.1 (95% CI: 13.40, 24.28) months, respectively. Most common treatment-emergent adverse events (TEAEs) were hyperphosphatemia (83%), stomatitis (72%), diarrhea (68%), dry mouth (51%), palmar-plantar erythrodysesthesia (51%); 42% of patients had serious TEAEs and 12% discontinued treatment due to an AE. No treatment-related deaths were observed. Conclusions: Data from pooled analysis of the RAGNAR and LUC2001 studies confirm robust efficacy of erdafitinib in a diverse population of patients with advanced or metastatic cholangiocarcinoma and prespecified FGFRfusions or mutations. Safety data were consistent with the erdafitinib safety profile. 1. Pant 2023. 2. Feng 2022. Clinical trial information: NCT04083976 and NCT02699606 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
好好好完成签到,获得积分10
1秒前
刻苦的小土豆完成签到 ,获得积分10
3秒前
Eva完成签到 ,获得积分10
3秒前
遇上就这样吧完成签到,获得积分0
4秒前
Abiu完成签到,获得积分10
5秒前
8秒前
kytm发布了新的文献求助10
8秒前
张辰熙完成签到 ,获得积分10
8秒前
科研小白完成签到 ,获得积分10
8秒前
疯狂的凡梦完成签到 ,获得积分10
10秒前
爆米花应助cyt9999采纳,获得10
11秒前
友好冥王星完成签到 ,获得积分10
11秒前
linmu完成签到 ,获得积分10
11秒前
15秒前
CodeCraft应助kytm采纳,获得10
16秒前
义气严青完成签到,获得积分10
19秒前
20秒前
大方大船完成签到,获得积分10
21秒前
爱吃煎饼果子的芋圆完成签到 ,获得积分10
21秒前
22秒前
不能随便完成签到,获得积分10
24秒前
qqq完成签到 ,获得积分10
25秒前
27秒前
就看最后一篇完成签到 ,获得积分10
33秒前
我爱Chem完成签到 ,获得积分10
33秒前
没有蛀牙发布了新的文献求助10
33秒前
35秒前
大侦探皮卡丘完成签到,获得积分10
37秒前
卿莞尔完成签到 ,获得积分0
37秒前
Steven发布了新的文献求助10
39秒前
明时完成签到,获得积分10
40秒前
李大刚完成签到 ,获得积分10
43秒前
44秒前
45秒前
Vaibhav完成签到,获得积分10
46秒前
天天快乐应助su采纳,获得10
46秒前
仿生人完成签到,获得积分10
47秒前
义气芷蝶完成签到 ,获得积分10
49秒前
结实凌瑶完成签到 ,获得积分10
50秒前
51秒前
高分求助中
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3965486
求助须知:如何正确求助?哪些是违规求助? 3510787
关于积分的说明 11155074
捐赠科研通 3245247
什么是DOI,文献DOI怎么找? 1792783
邀请新用户注册赠送积分活动 874096
科研通“疑难数据库(出版商)”最低求助积分说明 804171